SequelSEC

bioAffinity Technologies, Inc. BIAF

Services-Commercial Physical & Biological Research · CIK 0001712762 · Fiscal year ends 1231

Revenue
$5.90M
Fiscal year ended 2026-06-30
Operating income
-$12.38M
Fiscal year ended 2026-06-30
Free cash flow
-$11.56M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$22.60MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$5.02Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue3.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Commercial Physical & Biological Research filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue22.4%17th
Revenue YoY growth-34.2%17th
Net margin-242.0%27th
Current ratio2.60x71th
Operating margin-171.6%33th
SBC / revenue10.9%64th
CapEx / revenue1.0%38th
FCF margin-152.4%50th

bioAffinity Technologies, Inc. (BIAF) reported revenue of $5.90M and net income of -$15.19M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from bioAffinity Technologies, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.

Income

bioAffinity Technologies, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$5.90M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$12.38M
Net income-$15.19M
Research & development$1.42M
Weighted-average diluted sharesUnavailable
Pretax income-$15.18M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$11.35M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

bioAffinity Technologies, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$2.43M
Total assets$7.62M
Current assets$3.87M
Total liabilities$3.85M
Current liabilities$2.68M
Total equity incl. NCI$3.77M
Temporary (mezzanine) equityUnavailable
Inventory$82.38K
Accounts receivableUnavailable
Goodwill$1.40M
Long-term debtUnavailable
Accounts payable$969.84K

Cash flow

bioAffinity Technologies, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$11.47M
Capital expenditures$91.99K
Investing cash flow-$91.99K
Financing cash flow$13.19M
Net change in cash$1.63M
Stock-based compensation$932.53K
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$413.09K

Derived

bioAffinity Technologies, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$11.56M
Gross marginUnavailable
Operating margin-209.8%
FCF margin-195.9%
SBC / revenue15.8%
Current ratio1.44x
Revenue YoY growth-23.2%
Net margin-257.3%
R&D / revenue24.0%
CapEx / revenue1.6%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BIAF in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.